Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience

BACKGROUND: Patients with solid organ transplants (SOTs) have been excluded from programmed death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor clinical trials due to concern for allograft rejection. The use of immune checkpoint inhibitor therapy remains controversial in transplant pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastrointest Oncol
Main Authors: DeLeon, Thomas T., Salomao, Marcela A., Aqel, Bashar A., Sonbol, Mohamad B., Yokoda, Raquel T., Ali, Ahmad H., Moss, Adyr A., Mathur, Amit K., Chascsa, David M., Rakela, Jorge, Bryce, Alan H., Borad, Mitesh J.
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6286929/
https://ncbi.nlm.nih.gov/pubmed/30603124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2018.07.05
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados